A very significant decrease in the Fatality Rate is reported with its use.
Gustavo Aguirre Chang. Doctor graduated from the UNMSM, with Postgraduate degrees in Management and Occupational Health. Lima Peru. May 2, 2020.
The existing evidence regarding the use of Ivermectin in COVID-19 is reviewed. A report is also made of part of the cases treated at the local level. [In Spanish at the link above.]
A study recently published in the journal Antiviral Research obtained participants from 169 hospitals around the world, this study includes a high number of patients treated with Ivermectin: 704 and their corresponding 704 controls. The results of the study indicate that the Fatality Rate in patients who used Ivermectin was 6.1 times lower compared to patients who did not use Ivermectin (1.4 vs 8.5%, p <0.0001).
For his part, in the Dominican Republic, the Pulmonologist J. Tavares reports that he is treating 247 patients with Ivermectin with a favorable response in all cases and has not manifested any fatal case.
Similarly, at the local level, although to date there are not many documented cases, the case fatality rate has been 0% and it is also observed that in 100% of the cases treated with Ivermectin there is an improvement in the illness and resolution of fever within 48 hours of starting treatment.
A New Therapeutic Scheme is presented according to the Degree of Severity and Response to Treatment, drawn up based on the experience of patients treated locally.
In the final part, an evaluation of the Risk-Benefit of the use of Ivermectin is made, the Conclusion is given that, since there is practically no risk in its use, it is recommended to formalize its inclusion in the first line of therapeutic action for COVID-19.
Finally, Recommendations are given mainly related to the supply in Health Establishments throughout the country.
[-] i8wu | 1 points | Aug 24 2020 17:09:58
This is the synopsis in English by Megalabs.
IVERMECTIN in the first line of action therapy for COVID-19
A very significant decrease in the Fatality Rate is reported with its use.
Gustavo Aguirre Chang. Doctor graduated from the UNMSM, with Postgraduate degrees in Management and Occupational Health. Lima Peru. May 2, 2020.
The existing evidence regarding the use of Ivermectin in COVID-19 is reviewed. A report is also made of part of the cases treated at the local level. [In Spanish at the link above.]
A study recently published in the journal Antiviral Research obtained participants from 169 hospitals around the world, this study includes a high number of patients treated with Ivermectin: 704 and their corresponding 704 controls. The results of the study indicate that the Fatality Rate in patients who used Ivermectin was 6.1 times lower compared to patients who did not use Ivermectin (1.4 vs 8.5%, p <0.0001).
For his part, in the Dominican Republic, the Pulmonologist J. Tavares reports that he is treating 247 patients with Ivermectin with a favorable response in all cases and has not manifested any fatal case.
Similarly, at the local level, although to date there are not many documented cases, the case fatality rate has been 0% and it is also observed that in 100% of the cases treated with Ivermectin there is an improvement in the illness and resolution of fever within 48 hours of starting treatment.
A New Therapeutic Scheme is presented according to the Degree of Severity and Response to Treatment, drawn up based on the experience of patients treated locally.
In the final part, an evaluation of the Risk-Benefit of the use of Ivermectin is made, the Conclusion is given that, since there is practically no risk in its use, it is recommended to formalize its inclusion in the first line of therapeutic action for COVID-19.
Finally, Recommendations are given mainly related to the supply in Health Establishments throughout the country.
permalink